CoChat
Sign Up
PreprintCited by 28SARS-CoV-2 and COVID-19 ResearchAnimal Virus Infections Studiesvaccines and immunoinformatics approaches

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

Preclinical evaluation of a COVID-19 vaccine candidate based on a recombinant RBD fusion heterodimer of SARS-CoV-2

Open access
Barreiro, Antonio, Prenafeta, Antoni, Bech-Sabat, Gregori, Roca, Mercè, Mur, Eva Perozo, March, Ricard, González-González, Luis, Madrenas, Laia, Corominas, Júlia, Fernández, Alex, Moros, Alexandra, Cañete, Manuel, Molas, Mercè, Pentinat-Pelegrin, Thais, Panosa, Clara, Moreno, Alberto, Molas, Ester Puigvert, Vilarrassa, Eva Pol, Palmada, Jordi, Garriga, Carme, Cabañas, Teresa Prat, Iglesias-Fernández, Javier, Vergara-Alert, Júlia, Lorca-Oró, Cristina, Roca, Núria, Fernández-Bastit, Leira, Rodon, Jordi, Pérez, Mònica, Segalés, Joaquim, Pradenas, Edwards, Marfil, Silvia, Trinité, Benjamin, Ortiz, Raquel, Clotet, Bonaventura, Blanco, Julià, Pedroza, Jorge Díaz, Carrasco, Rosa Ampudia, Salgado, Yaiza Rosales, Loubat-Casanovas, Jordina, Larripa, Sara Capdevila, Prado, Julia Garcia, Barretina, Jordi, Sisteré-Oró, Marta, Rica, Paula Cebollada, Meyerhans, Andreas, Ferrer, Laura·2021·iScience
DOI 10.1101/2021.11.22.469117PMC PMC9893798

Preprint — published as 10.1016/j.isci.2023.106126 · Paper page

Open this paper in CoChat — free accountOpen PDF

Abstract

Summary: Current C0VID-19 vaccines have been associated with a decline in infection rates, prevention of severe disease and a decrease in mortality rates. However, SARS-CoV-2 variants are continuously evolving, and development of new accessible COVID-19 vaccines is essential to mitigate the pandemic. Here, we present data on preclinical studies in mice of a receptor-binding domain (RBD)-based recombinant protein vaccine (PHH-1V) consisting of an RBD fusion heterodimer comprising the B.1.351 and B.1.1.7 SARS-CoV-2 variants formulated in SQBA adjuvant, an oil-in-water emulsion. A prime-boost immunisation with PHH-1V in BALB/c and K18-hACE2 mice induced a CD4 + and CD8 + T cell response and RBD-binding antibodies with neutralising activity against several variants, and also showed a good tolerability profile. Significantly, RBD fusion heterodimer vaccination conferred 100% efficacy, preventing mortality in SARS-CoV-2 infected K18-hACE2 mice, but also reducing Beta, Delta and Omicron infection in lower respiratory airways. These findings demonstrate the feasibility of this recombinant vaccine strategy.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1101/2021.11.22.469117

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Flagged first, then by citations

Research works printed but not linked: 46

  1. 10.1038/s41562-021-01160-2 · DOI
  2. 10.3390/vaccines9101052 · DOI · Paper page
  3. 10.1101/2021.03.06.434193 · DOI
  4. 10.3390/vaccines9010039 · DOI
  5. 10.3390/pathogens9050331 · DOI
  6. 10.1101/2020.09.08.280818 · DOI · Paper page
  7. 10.1038/s41586-020-2951-z · DOI
  8. 10.1038/s41401-020-0485-4 · DOI
  9. 10.1038/s41423-020-0458-z · DOI
  10. 10.1038/s41586-021-04385-3 · DOI · Paper page
  11. 10.1038/s41392-020-00402-5 · DOI
  12. 10.1016/j.chom.2021.02.020 · DOI · Paper page
  13. 10.1038/s41577-020-00480-0 · DOI
  14. 10.1073/pnas.1707304114 · DOI · Paper page
  15. 10.1056/NEJMoa2026920 · DOI · Paper page
  16. 10.1101/2021.03.02.433390 · DOI
  17. 10.1016/s1473-3099(21)00147-x · DOI
  18. 10.1038/s41541-021-00292-w · DOI
  19. 10.1038/s41541-021-00393-6 · DOI
  20. 10.1016/j.cell.2020.09.037 · DOI · Paper page
  21. 10.1021/acscentsci.0c00742 · DOI
  22. 10.1016/j.chom.2021.02.003 · DOI · Paper page
  23. 10.1126/scitranslmed.abi9915 · DOI · Paper page
  24. 10.1038/s41564-020-00789-5 · DOI · Paper page
  25. 10.1016/S0264-410X(96)00183-1 · DOI
  26. 10.1101/2021.02.22.432359 · DOI
  27. 10.2174/1570163817666200312102137 · DOI
  28. 10.1038/s41598-020-77077-z · DOI
  29. 10.1038/s41467-020-20653-8 · DOI · Paper page
  30. 10.1038/s41598-021-81862-9 · DOI
  31. 10.1093/bioinformatics/bty407 · DOI · Paper page
  32. 10.1016/s2666-5247(21)00068-9 · DOI · Paper page
  33. 10.1086/317537 · DOI
  34. 10.1126/science.3107127 · DOI
  35. 10.1080/22221751.2022.2056524 · DOI
  36. 10.3389/fmicb.2022.840757 · DOI
  37. 10.1016/j.cell.2022.03.037 · DOI
  38. 10.1002/prot.21419 · DOI
  39. 10.1063/1.445869 · DOI
  40. 10.1021/acs.jctc.5b00255 · DOI
  41. 10.1021/ar000033j · DOI · Paper page
  42. 10.1002/pro.3943 · DOI
  43. 10.1016/j.medj.2021.01.005 · DOI
  44. 10.1016/j.vaccine.2011.05.016 · DOI
  45. 10.1080/22221751.2021.1913974 · DOI
  46. 10.1177/03009858211066841 · DOI

Metadata

Authors
Barreiro, A., Prenafeta, A., Bech-Sabat, G., Roca, M., Mur, E. P., March, R., González-González, L., Madrenas, L., Corominas, J., Fernández, A., Moros, A., Cañete, M., Molas, M., Pentinat-Pelegrin, T., Panosa, C., Moreno, A., Molas, E. P., Vilarrassa, E. P., Palmada, J., Garriga, C., Cabañas, T. P., Iglesias-Fernández, J., Vergara-Alert, J., Lorca-Oró, C., Roca, N., Fernández-Bastit, L., Rodon, J., Pérez, M., Segalés, J., Pradenas, E., Marfil, S., Trinité, B., Ortiz, R., Clotet, B., Blanco, J., Pedroza, J. D., Carrasco, R. A., Salgado, Y. R., Loubat-Casanovas, J., Larripa, S. C., Prado, J. G., Barretina, J., Sisteré-Oró, M., Rica, P. C., Meyerhans, A., & Ferrer, L.
Affiliations
  • Universitat Autònoma de Barcelona (ES)
  • Universitat de Vic - Universitat Central de Catalunya (ES)
  • Institut d'Investigació en Ciències de la Salut Germans Trias i Pujol (ES)
  • Universitat Pompeu Fabra (ES)
  • Institució Catalana de Recerca i Estudis Avançats (ES)
Corresponding author
  • Barreiro, Antonio
  • Prenafeta, Antoni
ORCID
Venue
iScience
Publisher
openRxiv
Published
2021-11-23
Volume
26
Issue
3
Pages
106126-106126
ISSN
2589-0042 (ISSN-L)
DOI
10.1101/2021.11.22.469117
PMC
PMC9893798
OpenAlex
W4318955566
Cited by
28
References
1
Citations by year
2026: 2 · 2025: 9 · 2024: 7 · 2023: 7 · 2022: 3
FWCI
5.17
Type
journal article
Language
en
Open access
Licence
cc-by-nc-nd
Locations
  • iScience (publishedVersion, cc-by-nc-nd)
  • bioRxiv (Cold Spring Harbor Laboratory) (acceptedVersion)
  • PubMed Central (publishedVersion, cc-by-nc-nd)
  • PubMed (publishedVersion)
  • Dipòsit Digital de Documents de la UAB (Universitat Autònoma de Barcelona) (submittedVersion, cc-by-nc-nd)
  • Repositori digital de la UPF (Universitat Pompeu Fabra) (submittedVersion, cc-by-nc-nd)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
  • IRTA (Institut de Recerca i Tecnologia Agroalimentaries) (submittedVersion, cc-by-nc-nd)
Topics
  • Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
  • Life Sciences › Agricultural and Biological Sciences › Animal Science and Zoology › Animal Virus Infections Studies
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › vaccines and immunoinformatics approaches
Keywords
COVID-19 vaccines, SARS-CoV-2, receptor binding domain, recombinant protein vaccine, oil-in-water emulsions, prime-boost vaccination, K18-hACE2 mice, Beta variant, Alpha variant, Omicron variant, Delta variant, neutralizing antibodies, T cell response, vaccine efficacy, vaccine tolerability

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review